VivoSeq
Dermatology

Dystrophic Epidermolysis Bullosa

9

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Dystrophic epidermolysis bullosa is an early-stage landscape with 9 programs across 8 companies. The most active players are Aegle Therapeutics, Lenus Therapeutics, LLC, Novartis. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aegle Therapeutics

1 program

Phase 2L

Lenus Therapeutics, LLC

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2CSL Behring logo

CSL Behring

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSProtein / enzyme117%Gene therapy117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 92% of 12 pipeline programs.

Analysis

Trial Status

12

clinical trials

Recruiting5 · 42%
Completed4 · 33%
Withdrawn1 · 8%
Terminated1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
Recruiting·AAnterogen Co., Ltd.·Phase 2·NCT05157958·6 enrolled
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
Recruiting·KKrystal Biotech, Inc.·Phase 3·NCT07016750·16 enrolled
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Recruiting·—·Phase 1/2·NCT06834035·8 enrolled
MSC EVs in Dystrophic Epidermolysis Bullosa
Recruiting·AAegle Therapeutics·Phase 1/2·NCT04173650·8 enrolled
Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa
Recruiting·IIsfahan University of Medical Sciences·Phase 1/2·NCT07230223·20 enrolled
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Active, not recruiting·AAbeona Therapeutics, Inc·Phase 3·NCT05725018·12 enrolled
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
Completed·VVanderbilt University Medical Center·Phase 2·NCT01538862·7 enrolled
Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients
Completed·EEgyptian Atomic Energy Authority·N/A·NCT03942250·8 enrolled
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
Completed·KKrystal Biotech, Inc.·Phase 3·NCT04917874·47 enrolled
Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.
Completed·XXinnate AB·Phase 1·NCT05378997·35 enrolled
Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
Terminated·LLenus Therapeutics, LLC·Phase 2·NCT03578029·4 enrolled
A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa
Withdrawn·HHealthpoint·Phase 2·NCT01528306

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)